日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab

Claudin 18.2 抗体佐贝妥昔单抗的临床药理学概况

Yang, Jianning; Yamada, Akihiro; Shitara, Kohei; Xu, Rui-Hua; Ilson, David; Lonardi, Sara; Klempner, Samuel J; Ueno, Yoko; Takeuchi, Masato; Pavese, Janet; Wojtkowski, Tomasz; Matsangou, Maria; Poondru, Srinivasu

Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

佐贝妥昔单抗治疗局部晚期不可切除或转移性胃/胃食管交界处腺癌患者的群体药代动力学和暴露-反应分析

Yamada, Akihiro; Takeuchi, Masato; Komatsu, Kanji; Bonate, Peter L; Poondru, Srinivasu; Yang, Jianning

Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

在局部晚期不可切除或转移性胃癌或胃食管交界处腺癌中,氟尿嘧啶和奥沙利铂在有或无佐贝妥昔单抗治疗下的群体药代动力学分析

Yamada, Akihiro; Yang, Jianning; Bonate, Peter L; Heo, Nakyo; Poondru, Srinivasu

Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

抗体药物偶联物恩福妥单抗在晚期尿路上皮癌和其他恶性实体瘤中的临床药理学研究

Tang, Mei; Garg, Amit; Bonate, Peter L; Rosenberg, Jonathan E; Matsangou, Maria; Kadokura, Takeshi; Yamada, Akihiro; Choules, Mary; Pavese, Janet; Nagata, Masanori; Tenmizu, Daisuke; Koibuchi, Akira; Heo, Nakyo; Wang, Lu; Wojtkowski, Tomasz; Hanley, William D; Poondru, Srinivasu

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

恩扎卢胺:了解和管理药物相互作用以提高患者安全性和药物疗效

Lennep, Brandon W; Mack, Jesse; Poondru, Srinivasu; Hood, Elizabeth; Looney, Brooke D; Williams, Monique; Bianco, Judeth J; Morgans, Alicia K

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

基于生理的药代动力学模型预测恩扎卢胺与P-gp和CYP3A底物联合用药的药物相互作用

Otsuka, Yukio; Poondru, Srinivasu; Bonate, Peter L; Rose, Rachel H; Jamei, Masoud; Ushigome, Fumihiko; Minematsu, Tsuyoshi

Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

恩扎卢胺对癌症患者P-gp和BCRP底物药代动力学的影响:CYP450诱导可能并不总是能预测对转运体的总体影响

Poondru, Srinivasu; Ghicavii, Vitalii; Khosravan, Reza; Manchandani, Pooja; Heo, Nakyo; Moy, Selina; Wojtkowski, Tomasz; Patton, Melanie; Haas, Gabriel P

A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma

一项随机II期研究比较了AGS-16C3F与阿昔替尼在既往接受过治疗的转移性肾细胞癌患者中的疗效

Kollmannsberger, Christian; Choueiri, Toni K; Heng, Daniel Y C; George, Saby; Jie, Fei; Croitoru, Ruslan; Poondru, Srinivasu; Thompson, John A

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

一项针对表皮生长因子受体突变型非小细胞肺癌患者的口服ASP8273的I期剂量递增研究

Yu, Helena A; Spira, Alexander; Horn, Leora; Weiss, Jared; West, Howard; Giaccone, Giuseppe; Evans, Tracey; Kelly, Ronan J; Desai, Bhardwaj; Krivoshik, Andrew; Moran, Diarmuid; Poondru, Srinivasu; Jie, Fei; Aoyama, Kouji; Keating, Anne; Oxnard, Geoffrey R

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

厄洛替尼联合林西替尼(OSI-906)或安慰剂治疗未接受过化疗且携带表皮生长因子受体激活突变的非小细胞肺癌患者的II期研究

Leighl, Natasha B; Rizvi, Naiyer A; de Lima, Lopes Gilberto Jr; Arpornwirat, Wichit; Rudin, Charles M; Chiappori, Alberto A; Ahn, Myung-Ju; Chow, Laura Q M; Bazhenova, Lyudmila; Dechaphunkul, Arunee; Sunpaweravong, Patrapim; Eaton, Keith; Chen, Jihong; Medley, Sonja; Poondru, Srinivasu; Singh, Margaret; Steinberg, Joyce; Juergens, Rosalyn A; Gadgeel, Shirish M